Peginterferon alfacon-1

Drug Profile

Peginterferon alfacon-1

Alternative Names: PEG INF alfacon-1; PEG-Alfacon; PEG-Infergen; PEG-interferon alfacon-1; Pegylated interferon alfacon-1

Latest Information Update: 04 Oct 2006

Price : $50

At a glance

  • Originator Amgen
  • Class Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 13 Mar 2006 Discontinued - Preclinical for Hepatitis C in Canada (SC)
  • 13 Mar 2006 Discontinued - Phase-II for Hepatitis C in USA (SC)
  • 03 Jun 2005 Data presented at the Digestive Disease Week and the 106th Annual Meeting of the American Gastroenterological Association (DDW-2005) have been added to the adverse events, pharmacokinetics and Viral infections pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top